Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Conditions
Duchenne Muscular Dystrophy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Phoenix Children's Hospital, Phoenix, Arizona, United States
Arkansas Childrens Hospital, Little Rock, Arkansas, United States
Contact: Study coordinator (Aravindhan Veerapandiyan, MD) · aveerapandiyan@uams.edu · (501) 364-1850Loma Linda University Pediatric Subspecialty Clinics, Loma Linda, California, United States
Contact: Principal Investigator (David Michelson, MD)Children's Hospital Los Angeles, Los Angeles, California, United States
Valley Children's Hospital, Madera, California, United States
Contact: Principal Investigator (Raymund David, MD)Stanford University, Palo Alto, California, United States
University of California, Davis, Sacramento, California, United States
Children's National Health System, Washington D.C., District of Columbia, United States
Contact: Study coordinator (Christopher Spurney, MD) · cspurney@childrensnational.org · 202-476-2185University of Florida Clinical and Translational Science Institue, Gainesville, Florida, United States
University of Miami, Miami, Florida, United States
Contact: Principal Investigator (Mario Saporta, MD)Nicklaus Children's Hospital, Miami, Florida, United States
Nemours Children's Hospital, Orlando, Florida, United States
Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
Contact: Principal Investigator (Matias Lopez Chacon, MD)Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Indiana University Health - Riley Hospital for Children, Indianapolis, Indiana, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
University of Massachusetts Memorial Medical Center, North Worcester, Massachusetts, United States
Contact: Study coordinator (Stephen M. Chrzanowski, MD, PhD) · Stephen.Chrzanowski@umassmed.edu · (774) 441-7615Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Masonic Children's Hospital - Discovery Clinic, Minneapolis, Minnesota, United States
Contact: Principal Investigator (Peter Karachunski, MD)The Children's Hospital at Montefiore, The Bronx, New York, United States
Contact: Principal Investigator (Carla Zingariello, DO)Atrium Health Neurosciences Institute, Charlotte, North Carolina, United States
Duke University Medical Center and Childrens Health Center, Durham, North Carolina, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Penn State Milton S. Hershey Medical Center- Penn State Hershey Neuroscience Institute, Hershey, Pennsylvania, United States
Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Neurology Rare Disease Center - Neurology & Neuromuscular Care Center, Denton, Texas, United States
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
University of Virginia Health System (UVAHS) - Pediatric Neuromuscular Center, Charlottesville, Virginia, United States
Seattle Children's Hospital, Seattle, Washington, United States
Children's Wisconsin, Milwaukee, Wisconsin, United States
Contact: Principal Investigator (Nancy Bass, MD)San Jorge Children's Hospital, San Juan, Puerto Rico, Puerto Rico
Contact: Principal Investigator (Edwardo Ramos, MD)FDI Clinical Research, San Juan, Puerto Rico, Puerto Rico
Contact: Study coordinator (Alexandra Montalvo Acevedo, MD) · alexandra.montalvo@fdipr.com · 787 722 1248
Study leads
William Andrews, MD
Study Director
Catalyst Pharmaceuticals
Aravindham Veerapandiyan, MD
Principal Investigator
Arkansas Childrens Hospital